Summary: Evaluated prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention (PCI). The primary endpoint of composite death from cardiovascular causes, nonfatal MI or nonfatal stroke was significantly reduced using prasugrel. There was also reduced target vessel revascularization and stent thrombosis. There was an increased risk of bleeding including life-threatening bleeding.
N Engl J Med. 2007 Nov 15;357(20):2001-15. Epub 2007 Nov 4.
Eponym: TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with Prasugrel - Thrombolysis In Myocardial Infarction 38